Obseva SA (NASDAQ:OBSV) has been assigned a consensus rating of “Buy” from the nine ratings firms that are presently covering the stock, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have covered the stock in the last year is $29.43.
Several research firms have weighed in on OBSV. Zacks Investment Research raised shares of Obseva from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research note on Thursday, October 18th. HC Wainwright set a $44.00 price target on shares of Obseva and gave the company a “buy” rating in a research report on Monday, October 15th. TheStreet upgraded shares of Obseva from a “d+” rating to a “c-” rating in a research report on Thursday, October 11th. Wedbush set a $34.00 price objective on shares of Obseva and gave the stock a “buy” rating in a report on Wednesday, October 3rd. Finally, JPMorgan Chase & Co. initiated coverage on shares of Obseva in a report on Thursday, September 13th. They issued an “overweight” rating and a $29.00 price objective on the stock.
Obseva stock opened at $14.84 on Tuesday. Obseva has a 1-year low of $9.05 and a 1-year high of $20.35. The company has a market capitalization of $559.29 million, a P/E ratio of -6.60 and a beta of 1.75.
Hedge funds and other institutional investors have recently made changes to their positions in the business. DRW Securities LLC lifted its stake in shares of Obseva by 55.0% in the 2nd quarter. DRW Securities LLC now owns 33,812 shares of the company’s stock valued at $512,000 after purchasing an additional 12,000 shares during the period. US Bancorp DE purchased a new position in Obseva during the second quarter worth about $197,000. Tiverton Asset Management LLC purchased a new position in Obseva during the second quarter worth about $224,000. Jane Street Group LLC purchased a new position in Obseva during the second quarter worth about $349,000. Finally, First Manhattan Co. lifted its position in shares of Obseva by 1.6% during the third quarter. First Manhattan Co. now owns 1,532,466 shares of the company’s stock worth $27,630,000 after purchasing an additional 23,500 shares in the last quarter. Institutional investors and hedge funds own 68.33% of the company’s stock.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Further Reading: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.